Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure

Heart Failure Clinical Trial

— ARNI-Sy  

Official title:

Influences of Angiotensin-neprilysin Inhibition With Sacubitril/Valsartan (ENTRESTO®) on Centrally Generated Sympathetic Activity in Heart Failure Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03415906
• Other study ID #: M17-05-LCZ-ARNI
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 14, 2017
• Est. completion date: September 6, 2018

Study information

• Verified date: October 2018
• Source: Hannover Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The autonomic nervous system plays an important role in controlling the circulation. Increased sympathetic activity has detrimental effects in patients with heart failure.

The purpose of this study is to test the hypothesis that combined angiotensin receptor + neprilysin inhibition results in lower sympathetic activity than angiotensin receptor inhibition alone.

Description:

Thirty-five heart-failure patients will be included in a prospective, monocentric, active-controlled, double-blind, cross-over study with randomized sequence of treatments sacubitril+valsartan or valsartan alone. After open-label dose finding and washout patients will be randomly assigned to the treatment sequence [sac+val --> val] or [val --> sac+val]. The two treatment periods of 4 weeks duration will be separated by 2 weeks of washout. At the end of both treatments the state of the cardiovascular system and its control will be measured.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 6, 2018
• Est. primary completion date: September 6, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Women or men at the age = 18 years, = 80 years and able to give written informed consent

2. Heart failure NYHA class II-III

3. Ejection fraction of 40 % or less

4. Stable dose of an ACE inhibitor or ARB over the last 4 weeks (A 2-day ACE inhibitor washout is scheduled before run-in; see Figure 3 on page 29.)

5. Stable dose of a beta-blocker over the last 4 weeks unless contraindicated or not tolerated

6. Patient has to be in sinus rhythm

7. Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial

8. Women without childbearing potential defined by:

• at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or

• hysterectomy or uterine agenesis or

• = 50 years and in postmenopausal state = 1 year or

• < 50 years and in postmenopausal state = 1 year with urine FSH > 40 IU/l and urine estrogen < 30 ng/l or a negative estrogen test OR

Women of childbearing potential with a negative urine ß-HCG pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 7 days following the last administration of study medication:

• correct use of at least an acceptable effective contraceptive measure. The following are deemed acceptable in this study: hormonal contraceptives (combined oral contraceptives and estrogen-free pills with desogestrel, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUS))

• true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)

• sexual relationship only with female partners and/or sterile male partners OR Male

9. Signed written informed consent and willingness to comply with treatment and follow- up procedures.

Exclusion Criteria:

1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACE inhibitors (ACE-Is), ARBs, or neprilysin inhibitors, as well as known or suspected contraindications to the study drugs

2. History of angioedema

3. Recent acute decompensated heart failure within 2 months before screening

4. Symptomatic hypotension and/or office systolic BP <110 mmHg at screening measured according to the recommendations of the European Society of Hypertension

5. Combined intake of an ACE inhibitor and ARB over the last 4 weeks

6. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²

7. Concomitant medication with Aliskiren in patients with Diabetes or patients with eGFR < 60 mL/min/1.73 m²

8. Serum potassium >5.2 mmol/L at Visit 1 (screening)

9. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid, or other major cardiovascular surgery, PCI, or carotid angioplasty within the 3 months before screening

10. History of heart transplant or on a transplant list or with LV assistance device

11. History of severe pulmonary disease

12. Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months prior to Visit 1

13. Presence of hemodynamically significant mitral and/or aortic valve disease/ left ventricular outflow tract obstruction, except mitral regurgitation secondary to LV dilatation

14. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs

15. Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2× upper limit of normal at Visit 1, history of hepatic encephalopathy, history of esophageal varices, or history of porto-caval shunt

16. Contraindications precluding microneurography measurements, such as relevant peripheral neuropathy as judged by the investigator

17. Pregnancy or lactation period

18. Current participation in any other clinical trial or participation in another clinical trial within 30 days before screening

19. Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal products

20. Vulnerable subjects (i.e. persons under any administrative or legal supervision or persons kept in detention)

Related Conditions & MeSH terms

• Heart Failure

Intervention

Combination Product:
• sacubitril+valsartan
Combined angiotensin receptor + neprilysin inhibition

Drug:
• valsartan
Angiotensin receptor inhibition alone

Locations

Country	Name	City	State
Germany	Clinical Research Center Hannover, Hannover Medical School	Hannover

Sponsors (2)

Lead Sponsor	Collaborator
Hannover Medical School	DLR German Aerospace Center

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	GLS [%]	Echocardiography: Global longitudinal strain as assessed using the speckle tracking technique	For 10 seconds at the end of both treatments
Other	E/E' [ratio]	Echocardiography: E = mitral peak velocity of early filling E' = early diastolic mitral annular velocity (mean of E' lateral and E' septal) E and E' are obtained from 3 or 5 heart cycles with sinus rhythm or atrial fibrillation, respectively.	For 10 seconds at the end of both treatments
Other	sPAP [mmHg]	Echocardiography: Systolic pulmonary arterial pressure obtained from 3 or 5 heart cycles with sinus rhythm or atrial fibrillation, respectively.	For 10 seconds at the end of both treatments
Other	HR variability [ms²]	ECG RR-interval oscillations	For 5 minutes at the end of both treatments
Other	BP variability [mmHg²]	Blood pressure oscillations	For 5 minutes at the end of both treatments
Other	Echocardiographic parameters	Cardiac dimension and function as assessed by echocardiography	For 20 minutes at the end of both treatments
Primary	MSNA burst frequency [bursts/min]	Bursts of vasoconstrictor sympathetic nerve activity directed to skeletal muscle (muscle sympathetic nerve activity, MSNA) per minute	For 5 minutes at the end of both treatments
Secondary	DBP [mmHg]	Diastolic blood pressure	For 5 minutes at the end of both treatments
Secondary	PVN activity [unitless]	Using functional Magnetic Resonance Imaging (fMRI) with concurrent Lower Body Negative Pressure (LBNP), we will identify the paraventricular hypothalamic nucleus (PVN) by its activity change from low to high LBNP stimulation in a 20-minute paradigm. Activity will be reported as a z-scores (no unit) averaged over the entire activation cluster.	For 20 minutes at the end of both treatments
Secondary	NTS activity [unitless]	Using functional Magnetic Resonance Imaging (fMRI) with concurrent Lower Body Negative Pressure (LBNP), we will identify the nucleus of the solitary tract (NTS) by its activity change from low to high LBNP stimulation in a 20-minute paradigm. Activity will be reported as a z-scores (no unit) averaged over the entire activation cluster.	For 20 minutes at the end of both treatments
Secondary	MSNA burst incidence [bursts/100 heartbeats]	Bursts of vasoconstrictor sympathetic nerve activity normalized to heart rate	For 5 minutes at the end of both treatments
Secondary	MSNA burst area [au/min]	Area under the bursts in the integrated neurogram of vasoconstrictor sympathetic nerve activity	For 5 minutes at the end of both treatments
Secondary	Cardiac baroreflex gain [ms/mmHg]	Ratio between the changes in ECG RR interval and systolic blood pressure	For 5 minutes at the end of both treatments
Secondary	Sympathetic baroreflex gain [bursts/mmHg]	Ratio between the changes in burst frequency and diastolic blood pressure	For 5 minutes at the end of both treatments
Secondary	Sympathetic excitability [bursts]	Increase in burst frequency elicited by isometric exercise (handgrip)	For 3 minutes at the end of both treatments
Secondary	NE [nM]	Venous plasma norepinephrine level	After 20 minutes of supine rest at the end of both treatments